Summary Inactivation of the tumour-suppressor gene p53 has been described as one of the most common molecular changes found in lung tumours. Our purpose was to study the prognostic value of p53 alterations and to determine whether some specific mutation type in the p53 gene could be associated with poor clinical evolution in non-small-cell lung cancer (NSCLC) patients. To this end, we studied 81 resected primary NSCLCs in order to detect p53 alterations. p53 protein accumulation was analysed using immunohistochemistry methods; p53 gene mutations in exons 5-9 were studied using polymerase chain reaction-single-strand conformation polymorphism and sequencing techniques. p53 protein was immunodetected in 46.9% of lung carcinomas and 44.7% of p53-immunopositive tumours showed p53 mutations. Survival analysis was performed on 62 patients. No survival differences were found for patients with or without p53 immunopositivity. A shorter survival was found in patients with underlying p53 gene mutations, mainly in patients with squamous cell lung tumours; the worst prognosis was found when mutations were located in exon 5 (P= 0.007). In conclusion, the location of p53 mutations might be considered as a prognostic indicator for the evaluation of poor clinical evolution in NSCLC patients.
Lung carcinomas constitute one of the leading causes of cancer mortality in the world and is the leading cause in the United States. Lung tumours are classified on the basis of histological type. The two main types are small-cell lung cancer (SCLC) and non-smallcell lung cancer (NSCLC). Non-small-cell lung cancer constitutes the majority group and consists of adenocarcinomas, squamous cell carcinomas, large-cell carcinomas and other rare types (Travis et al, 1995) .
Inactivation of tumour-suppressor gene p53 has been shown to be involved in the development of non-small-cell lung cancer (Passlick et al, 1994) . The p53 gene encodes a nuclear phosphoprotein that is a potent transcriptional activator with a DNAbinding domain in its C-terminal region (Kern et al, 1991; Ullrich et al, 1992 ). Several reports demonstrate that the p53 protein has an important role in the negative regulation of the cell cycle, arresting cells in G, phase in response to DNA damage (Kuerbitz et al, 1992; Smith et al, 1995) . The elevation of p53 protein levels in response to DNA damage leads to activation of the transcription of certain genes regulated by p53, such as an inhibitor of cyclindependent kinase activity (p21/CIP/WAF) (El-Deiry et al, 1993; Dulic et al, 1994) . Additionally, p53 is involved in apoptosis mechanisms (Claire and Fisher, 1995; Guillouf et al, 1995) .
Missense mutations in exons 5-8 are the most frequent abnormality detected in the p53 gene. These mutations lead to stabilization of the protein in the nucleus. While the wild-type p53 protein has a half-life of less than 30 min, the mutated p53 protein has a half-life of several hours (Finlay, 1992) . For this reason, routine immunohistochemistry methods have been used to detect the abnormal protein and, usually, protein accumulation data have been correlated with p53 gene mutations. However, recent data suggest that the presence of the p53 protein stabilized in the nucleus does not always guarantee an underlying mutation of the gene (Bourdon et al, 1995; Top et al, 1995) .
Regarding the prognostic role of p53, in almost all studies testing human NSCLC, p53 abnormalities in the gene have been associated with a poor survival rate (Horio et al, 1993; Mitsudomi et al, 1993) . However, other authors have found a better outlook in patients with p53-mutated tumours (Top et al, 1995) . Whereas some studies have reported a favourable prognosis linked to p53 protein stabilization in the nucleus (Lee et al, 1995) , others have found a clinical correlation with poor prognosis (Quinlan et al, 1992; Carbone, 1994) or no association (Passlick et al, 1995) .
In order to clarify these conflicting studies, we investigated 81 tumours from patients affected by non-small-cell lung cancer and subjected to radical surgery to detect p53 abnormalities. The objectives of our work were, firstly, to establish whether these genetic alterations have any relationship to clinicopathological features or shortened survival and, secondly, to determine whether some specific type of mutation in the p53 gene could be associated with a poor clinical evolution in NSCLC patients.
MATERIALS AND METHODS Patients and tumour samples
The study population consisted of 81 patients (79 men and two women), with a median age of 62.2 ± 9.25 years, who had undergone surgery for lung carcinoma between 1990 and 1994 at San Carlos Hospital in Madrid. Preoperative evaluation included: chest radiography, fibreoptic bronchoscopy and biopsy, when possible; (Mountain, 1986) . Thirty-seven patients (46%) had stage I tumours; five (6%) had stage II; 30 (37%) had stage IIIA; four (5%) had stage HIB; and five (6%) had stage IV tumours. Patients who had stages I, II and IIIA tumours were subjected to curative surgery, whereas only a biopsy was taken from patients who suffered from more extensive disease (tumours in stage IIIB and IV).
All genetic alterations were detected in tumour samples containing more than 80% tumour cells. To confirm this, cryostatsectioned haematoxylin-eosin-stained samples from each tumour block were examined microscopically by two independent pathologists. In all cases, non-tumour tissues were used as a control. Non-tumour samples were selected from macroscopically normal areas of surgical specimens.
All tumours were typed according to World Health Organization (WHO) criteria (Sobin, 1982) (Hsu et al, 1981) and polyclonal antibody (PAb) 1801 (Oncogene nuclei ranged from 50% to 100%. In 17 cases, about 30% of the tumour cells had stained nuclei. Seven positive cases had 10% of the tumour cell nuclei staining for p53 antigen. Therefore, samples scored as positive for p53 expression exhibited intense nuclear staining in more than 10% of the tumour epithelium but not in adjacent normal epithelial or stromal tissue. (Banks et al, 1986) . As a positive control, a section of a lung carcinoma with high p53 expression was included in all the assays performed, and the corresponding normal tissue was used as a negative control. Sections of tumours were examined for evidence of nuclear staining with a semiquantitative assessment of signal intensity and proportion of cells staining. In 14 cases, the density of positive p53 gene mutations analysis To assess whether immunopositivity for p53 protein correlates with the presence of structural alterations in the gene, we identified p53 mutations in exons 5-9 using more labour-intensive methods, such as single-strand conformation polymorphism (SSCP) and sequencing. We analysed frozen surgical tumour specimens and their corresponding normal tissue from all 81 patients studied. DNA isolation from fresh tumour and non-tumour tissue was performed using the DNA extraction protocol described by Blin and Stafford (1976) .
Polymerase chain reaction-single-strand conformation polymorphism analysis (PCR-SSCP)
Analysis of single-strand conformation polymorphism (SSCP) was performed as described by Orita et al (1989) . DNA samples were amplified for SSCP analysis from exons 5, 6, 7, 8 and 9 of the p53 gene. Each amplification reaction was carried out in a 10-,ul reaction volume containing: 0.1 tg of genomic DNA, 1 gM of each primer, 0.2 mm of each deoxynucleoside triphosphate, 10 mM Tris HCI (pH 8.3), 50 mm potassium chloride, 2 mm magnesium chloride, 0.5 U of Taq DNA Polymerase (Perkin Elmer, Roche, NJ, USA) and 0.5 gl [cX-32P] dCTP (3000 Ci mmol-') (Nuclear Iberica, Spain). Reaction mixtures were subjected to 30 cycles of the PCR at 94°C, 55°C and 72°C for 0.5, 0.5 and 1 min, respectively, in a Perkin Elmer thermocycler (Gene Amp PCR System 2400). The primers used and the length of fragments are shown in Table 1 . An aliquot of the PCR-SSCP reaction mixture (1 ,ul) was diluted in 100 ,ul of 0.1% sodium dodecyl sulphate (SDS), 10 mM EDTA.
Then, 10 gl of this solution was mixed with 10 p1 of 95% formamide, 20 mm EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol, heated at 95°C and applied (1 ,ul per lane) to a 6% polyacrylamide gel containing 90 mM Tris borate (pH 8.3), 2 mM EDTA and 10% glycerol. Electrophoresis was performed at 30 W for 4-6 h under continuous cooling. Finally, the gel was dried and exposed to radiographic film at room temperature for 12-24 h. The above protocol yielded the highest sensitivity for p53 mutations compared with several variations of this procedure, including changes in the gel glycerol content and in the temperature of electrophoresis. In our hands, SSCP can detect mutations in the presence of 90% contaminating normal tissue. Moreover, the sensitivity of the SSCP method was checked by known mutations selected from a colorectal tumour population previously analysed in our laboratory. (Figure 1 ), were always found in lung tumours that were positive for p53 protein staining in the nucleus. However, only 44.7% of p53-immunopositive tumours showed underlying p53 gene mutations in exons 5-9.
A non-significant correlation was found between p53 gene mutation and tumour stage, histology or differentiation grade. For the differentiation grade, we found a trend toward accumulation of p53 gene mutations in moderately or poorly differentiated tumours, but the differences were not found to be significant (Table 2 ).
All positive tumours for p53 gene mutations showed heterozygosity as, in all cases, only one of the alleles was altered. Among these mutations, 58.8% were located in exon 5 (20% transversions and 80% transitions); 29.4% in exon 7 (60% transversions and 40% transitions) and 11.8% in exon 8 (50% transversions and 50% transitions) (Table 3) . Therefore, of all the mutations detected, 64.7% were transition type. All 17 patients bearing p53 gene mutation showed single-point mutations. Among those, 15 were missense mutations (88.2%) and two were silent mutations (11.8%) ( 
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DISCUSSION
Changes in p53 are among the most common molecular events found in all types of lung tumours, suggesting a crucial role forpS3 in bronchial carcinogenesis. However, the prognostic significance of p53 abnormalities in lung cancer is still poorly understood. We have detected p53 immunostaining in 46.9% of lung tumours analysed, which corresponds to the findings previously reported in the literature (Passlick et al, 1995) using the same antibody PAb 1801. Other authors have published higher percentages using different antibodies (Lee et al, 1995) . According to our results, only 44.7% of p53-immunopositive tumours have underlying gene mutations in exons 5-9. In Table 6 , we summarize different studies evaluating p53 molecular abnormalities and/or p53 protein accumulation in NSCLC patients. In this table, we show the lack of concordance, reported by different authors, between p53 protein nuclear accumulation and p53 gene mutations. Carbone et al (1994) found a concordance of 67%, Fujino et al (1995) 75%, Top et al (1995) 68%, and Shipman et al (1996) reported that the concordance between p53 protein accumulation and p53 gene mutation data was only of 53%. Therefore, it seems clear that investigation for p53 abnormalities requires molecular studies, and immunostaining positivity should not be taken as equivalent to molecular abnormality in the gene.
The lack of correlation between p53 immunostaining and p53 mutation data found in this work could in fact be accounted for by the presence of missense mutations outside exons 5-9 leading to protein accumulation. Some studies of mutations outside this region, in different types of tumours, suggest that 10-25% of all mutations occur outside exons 5-8, but in these regions there is a predominant pattern of null mutations (Hartmann et al, 1995) that do not result in protein accumulation. Another explanation for the lack of concordance between p53 accumulation and gene mutations could be the concurrent stabilization of p53 protein as it is bound and inactivated by endogenous proteins, such as mdm-2 (Momand et al, 1992) or by exogenous DNA tumour virus proteins (Scheffner et al, 1990) . Other mechanisms could be proposed considering the important role played by p53 in the regulation of the cell cycle (Kuerbitz et al, 1992; Guillouf et al, 1995; . In this regard, p53 protein could be overexpressed to activate certain genes regulated by p53, such as p21/CIP/WAF (El-Deiry et al, 1993; Dulic et al, 1994) , whose protein product binds and inactivates CDK4, arresting cells at the G1/S transition of the cell cycle and allowing p53 to repair the DNA damage. In addition, p53 protein is also induced during cell death by apoptosis (Claire and Fisher, 1995; Guillouf et al, 1995) . Wild-type p53 protein overexpression and accumulation in the cellular nucleus may activate apoptosis as a protection mechanism throughout tumorigenesis.
We have found a rate of 21% for p53 gene mutation. Data reported in the literature for resected NSCLC vary greatly (Table   6 ). Thus, in the most recent molecular studies on p53, we find incidences for p53 gene mutations in NSCLC varying from 51% (Carbone et al, 1994) to 25% (Fong et al, 1995) .
We also report a lack of correlation between p53 protein or gene alterations and clinicopathological tumour characteristics, such as tumour stage and histology. In other lung tumour series, p53 mutations have been associated with tumours of squamous cell histology (Mitsumomi et al, 1993) . However, a significant association was found between p53 protein accumulation and differentiation grade, p53 overexpression or mutation being prevalent in poorly differentiated lung tumours. These results could indicate British Journal of Cancer (1997) 76(1), [44] [45] [46] [47] [48] [49] [50] [51] . Cancer Research Campaign 1997 the participation of p53 alterations in the cell dedifferentiation process.
In our tumour population, we have identified 17 p53 mutations. Eleven of these (64.7%) represented transition mutations, a frequency which differs from that reported by other authors in NSCLC (Chiba et al, 1990) . However, in other tumours p53 mutations commonly involve G to A transitions and, in general, the type of mutation reflects the mutagen involved as specific mutational spectra are associated with individual mutagens. For example, in some situations, benzo[a]pyrene can cause G to T transversions (Chiba et al, 1990) , while alkylator exposure resulting in the production of 06-methylguanine causes predominantly G to A transitions (Loechler et al, 1984) . Thus, the pattern of p53 mutations in different series of lung tumour carcinomas may be attributed to exposure to different mutagens.
While the importance of p53 mutations in the pathogenesis of human lung cancer is well established, it is not clear whether the presence or absence of p53 mutations or overexpression of p53 protein adversely affects an individual patient's chances for survival. In fact, there is significant controversy over the prognostic importance of abnormalities in the p53 gene in resected NSCLC, and only a few authors have evaluated both molecular abnormalities and protein overexpression in a cohort of patients with adequate staging and follow-up (Table 6 ). Regarding the effect of p53 protein stabilization on the clinical evolution of patients, our data indicated that p53 immunopositivity was not associated with a poor prognosis in non-small-cell lung carcinomas. However, contradictory studies have been published regarding p53 immunopositivity as a prognostic indicator in NSCLC. Some investigators have associated nuclear staining with a favourable prognostic influence in lung cancer (Lee et al, 1995; Passlick et al, 1994) . Recently, Passlick et al (1995) reported that p53 protein overexpression is not associated with an unfavourable prognosis in patients with early-stage NSCLC. Passlick et al (1995) considered that wild-type p53 protein overexpression might reflect a specific cellular response to certain carcinogens. Thus, lung tumour cells with high amounts of wild-type p53 might be able to protect themselves more effectively against exogenous DNA-damaging agents. Other authors investigating p53 protein, however, have reported that p53 immunopositivity is a negative prognostic factor in NSCLC (Quinlan et al, 1992; Carbone, 1994) . Finally, no differences in prognosis have been found by others (Brambilla et al, 1993) .
Regarding p53 mutations and the clinical evolution of lung cancer patients, our results indicate that p53 gene mutations predict a shorter survival in NSCLC patients. The group of squamous cell carcinoma patients with this alteration showed the worst prognosis. The presence of p53 mutations in this group of patients was an independently significant parameter as established from the multivariate statistical analysis. A few studies can be found in the literature examining p53 gene alterations in relationship to clinical evolution of NSCLC patients. These studies describe, in general, p53 gene mutations as a significant indicator of poor prognosis (Horio et al, 1993; Mitsudomi et al, 1993) . Moreover, we found a significant poor clinical evolution when p53 mutation was located at exon 5, a borderline independent significant parameter, the group of squamous cell carcinoma patients with this alteration showing the worst prognosis. In spite of p53 exon 5 mutations being associated with a significant increase in the risk of death from breast cancer (Seshadri et al, 1996) and with lympho proliferative disorders (Gandini et al, 1996) , this is the first study analysing NSCLC series in which a correlation has been established between the location of the p53 gene mutation and the clinical evolution of patients. p53 exon 5 encodes for amino acids 126-186 in the protein, which is part of the central 'core' domain (residues 102-292) that is essential for sequence-specific DNA binding. Missense point mutations within this domain abolish p53-suppressor function and are linked with the development of over half of all human cancers. There is evidence that mutations in the central core domain appear to cause p53 to adopt an alternative 'mutant' conformation. Some mutants can be induced to fold back into the wild-type form, recovering specific DNA binding function (Milner, 1995) .
In conclusion, our results indicate that p53 exon 5 mutations correlate with a poorer survival in patients affected by NSCLC, mainly in patients with squamous cell lung tumours. Moreover, our data also indicate the need for further molecular studies to investigate p53 abnormalities, as p53 protein immunopositivity does not always guarantee the presence of gene alterations. Characterization of p53 mutation type could be used as a prognostic indicator of poor clinical evolution in NSCLC patients to evaluate the benefit of adjuvant therapy in patient populations submitted to radical surgery.
